The History and Development of HER2 Inhibitors

Xiaohui Xia; Chen Gong; Yinan Zhang; Huihua Xiong

doi:10.3390/ph16101450

The History and Development of HER2 Inhibitors

Pharmaceuticals (Basel). 2023 Oct 12;16(10):1450. doi: 10.3390/ph16101450.

Authors

Xiaohui Xia¹, Chen Gong¹, Yinan Zhang², Huihua Xiong¹

Affiliations

¹ Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
² School of Chemical Science and Engineering, Tongji University, Shanghai 200092, China.

Abstract

HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.

Keywords: HER2 inhibitors; antibodies; antibody-drug conjugates; cancer; tyrosine kinase inhibitors.

Publication types

Review

Grants and funding

This research received no external funding.